Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amlodipine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
3Z Unveils Study Supporting Calcium Channel Blocker for ADHD Therapy
Details : 3Z-20-003 (amlodipine) is an L-type calcium channel blocker (LTCC), being investigated as a novel therapy for attention-deficit/hyperactivity disorder.
Product Name : 3Z-20-003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : Amlodipine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Discovery
Sponsor : biotx.ai
Deal Size : Undisclosed
Deal Type : Partnership
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling
Details : The partnership aims at revolutionizing ADHD drug development by leveraging advanced AI modelling techniques to bridge the gap between animal studies and human clinical trials, enabling a more efficient and accurate translation of promising therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Sponsor : biotx.ai
Deal Size : Undisclosed
Deal Type : Partnership